ExeVir Bio BV (“ExeVir”), announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.
Torsten Mummenbrauer, Chief Executive Officer of ExeVir will be speaking on a panel discussion titled “Advances in Covid Therapeutics” taking place at 11.00 CET on Wednesday 6th October 2021 and chaired by Max Herrmann, Managing Director, Stifel Financial Corp.
The main programme for the 8th Annual HTIF is spread throughout 2 days (5th-6th of October) and will include HealthTech Innovation Day, focusing on Investment & Partnership in MedTech and Digital Health, and Managing Covid-19 Pandemic & Future Global Threats Day, which will include keynotes covering global supply chain and diagnostics.
Attend the talk of our CEO, Torsten Mummenbrauer, or connect with our team on the networking tool to learn more about ExeVir Bio.
More information on the event website.